Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL)

Neoplasma

Volumn 60, Issue 2, 2013, Pages 223-231

  Leahomschi, S ^a   Molinsky, J ^a,b   Klanova, M ^a,b   Andera, L ^c   Peterka, M ^c   Gasova, Z ^d   Klener Sr , P ^b,d   Trneny, M ^b,d   Necas, E ^a   Simonova, T ^a   Zivny, J ^a   Klener Jr , P ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Apoptosis; BCL2 family; Drug resistance; Leukemia; TRAIL

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CASPASE 8; CYTARABINE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; IMATINIB; PROTEIN BAD; PROTEIN BAK; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL STRAIN K 562; DRUG RESISTANCE; SIGNAL TRANSDUCTION;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876137090     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_030     Document Type: Article

References (44)

1. WILEY SR, SCHOOLEY K, SMOLAK PJ, DIN WS, HUANG CP et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682. http://dx.doi.org/10.1016/1074-7613(95)90057-8
2. SHERIDAN JP, MARSTERS SA, PITTI RM, GURNEY A, SKUBATCH M et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821. http://dx.doi.org/10.1126/science.277.5327.818
3. PITTI RM, MARSTERS SA, RUPPERT S, DONAHUE CJ, MOORE A et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690. http://dx.doi.org/10.1074/jbc.271.22.12687
4. PORDZIK S, PETROVICI K, SCHMID C, KROELL T, SCHWEIGER C et al. Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia. Hematology 2011; 16: 341-350. http://dx.doi.org/10.1179/102453311X13127324303353
5. LI Y, JIN X, LI J, JIN X, YU J et al. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Urology 2012; 79: 968-15. http://dx.doi.org/10.1016/j.urology.2011.11.011
6. CHAMULEAU ME, OSSENKOPPELE GJ, VAN RHENEN A, VAN DREUNEN L, JIRKA SM et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res 2011; 35: 741-749. http://dx.doi.org/10.1016/j.leukres.2010.12.032
7. MCLORNAN DP, BARRETT HL, CUMMINS R, MCDERMOTT U, MCDOWELL C et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-3451. http://dx.doi.org/10.1158/1078-0432.CCR-10-0052
8. MACHER-GOEPPINGER S, AULMANN S, TAGSCHERER KE, WAGENER N, HAFERKAMP A et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res 2009; 15: 650-659. http://dx.doi.org/10.1158/1078-0432.CCR-08-0284
9. GRANCI V, BIBEAU F, KRAMAR A, BOISSIERE-MICHOT F, THEZENAS S et al. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008; 44: 2312-2318. http://dx.doi.org/10.1016/j.ejca.2008.06.042
10. KOKSAL IT, SANLIOGLU AD, KARACAY B, GRIFFITH TS, SANLIOGLU S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158-165. http://dx.doi.org/10.1016/j.urolonc.2007.01.022
11. VAN GEELEN CM, WESTRA JL, DE VRIES EG, BOERSMAVAN EK W, ZWART N et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006; 24: 4998-5004. http://dx.doi.org/10.1200/JCO.2006.06.8809
12. ZHUANG L, LEE CS, SCOLYER RA, MCCARTHY SW, ZHANG XD et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37: 1286-1294. http://dx.doi.org/10.1016/j.humpath.2006.04.026
13. KUIJLEN JM, MOOIJ JJ, PLATTEEL I, HOVING EW, VAN DER GRAAF WT et al. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006; 78: 161-171. http://dx.doi.org/10.1007/s11060-005-9081-1
14. ASHKENAZI A, HOLLAND P, ECKHARDT SG. Ligandbased targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-3630. http://dx.doi.org/10.1200/JCO.2007.15.7198
15. HERBST RS, ECKHARDT SG, KURZROCK R, EBBINGHAUS S, O'DWYER PJ et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-2846. http://dx.doi.org/10.1200/JCO.2009.25.1991
16. HOTTE SJ, HIRTE HW, CHEN EX, SIU LL, LE LH et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-3455. http://dx.doi.org/10.1158/1078-0432.CCR-07-1416
17. SORIA JC, SMIT E, KHAYAT D, BESSE B, YANG X et al. Phase 1b study of dulanermin (recombinant human Apo2L/ TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous nonsmall-cell lung cancer. J Clin Oncol 2010; 28: 1527-1533. http://dx.doi.org/10.1200/JCO.2009.25.4847
18. LEONG S, COHEN RB, GUSTAFSON DL, LANGER CJ, CAMIDGE DR et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27: 4413-4421. http://dx.doi.org/10.1200/JCO.2008.21.7422
19. LU X, ARBISER JL, WEST J, HOEDT-MILLER M, SHERIDAN A et al. Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol 2004; 165: 1613-1620. http://dx.doi.org/10.1016/S0002-9440(10)63418-9
20. MOLINSKY J, KLANOVA M, KOC M, BERANOVA L, ANDERA L et al. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Leuk Lymphoma 2012. http://dx.doi.org/10.3109/10428194.2012.710331
21. KIM HB, KIM MJ, KIM DY, LEE JW, BAE JH et al. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer 2011; 10: 46. http://dx.doi.org/10.1186/1476-4598-10-46
22. FRENZEL LP, PATZ M, PALLASCH CP, BRINKER R, CLAASEN J et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011; 152: 191-200. http://dx.doi.org/10.1111/j.1365-2141.2010.08426.x
23. CARTER BZ, MAK DH, SCHOBER WD, DIETRICH MF, PINILLA C et al. Triptolide sensitizes AML cells to TRAILinduced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742-3750. http://dx.doi.org/10.1182/blood-2007-05-091504
24. KIM YH, PARK JW, LEE JY, KWON TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25: 1813-1820. http://dx.doi.org/10.1093/carcin/bgh188
25. FULDA S, DEBATIN KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-346. http://dx.doi.org/10.1158/0008-5472.CAN-03-1656
26. HU L, CAO D, LI Y, HE Y, GUO K. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer Biol Ther 2012; 13: 516-526. http://dx.doi.org/10.4161/cbt.19601
27. ALLEN JE, FERRINI R, DICKER DT, BATZER G, CHEN E et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012. http://dx.doi.org/10.1158/1535-7163.MCT-12-0366
28. TUR V, VAN DER SLOOT AM, REIS CR, SZEGEZDI E, COOL RH et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283: 20560-20568. http://dx.doi.org/10.1074/jbc.M800457200
29. RICCIONI R, PASQUINI L, MARIANI G, SAULLE E, ROSSINI A et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624.
30. CHAMULEAU ME, OSSENKOPPELE GJ, VAN RHENEN A, VAN DREUNEN L, JIRKA SM et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res 2011; 35: 741-749. http://dx.doi.org/10.1016/j.leukres.2010.12.032
31. SEAL S, HOCKENBERY DM, SPAULDING EY, KIEM HP, ABBASSI N et al. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol 2008; 36: 1660-1672. http://dx.doi.org/10.1016/j.exphem.2008.07.012
32. GUO F, SIGUA C, BALI P, GEORGE P, FISKUS W et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005; 105: 1246-1255. http://dx.doi.org/10.1182/blood-2004-05-2041
33. DIDA F, LI Y, IWAO A, DEGUCHI T, AZUMA E et al. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp Hematol 2008; 36: 1343-1353. http://dx.doi.org/10.1016/j.exphem.2008.04.011
34. INUKAI T, ZHANG X, GOTO M, HIROSE K, UNO K et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006; 20: 2119-2129. http://dx.doi.org/10.1038/sj.leu.2404429
35. CHENG J, HYLANDER BL, BAER MR, CHEN X, REPASKY EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006; 5: 1844-1853. http://dx.doi.org/10.1158/1535-7163.MCT-06-0050
36. HAO XS, HAO JH, LIU FT, NEWLAND AC, JIA L. Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis. Apoptosis 2003; 8: 601-607. http://dx.doi.org/10.1023/A:1026131425204
37. KLENER P, JR., LEAHOMSCHI S, MOLINSKY J, SIMONOVA T, NECAS E et al. TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine. Blood Cells Mol Dis 2009; 42: 77-84. http://dx.doi.org/10.1016/j.bcmd.2008.10.002
38. AKAHANE K, INUKAI T, ZHANG X, HIROSE K, KURODA I et al. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis. Exp Hematol 2010; 38: 885-895. http://dx.doi.org/10.1016/j.exphem.2010.06.014
39. DELIGEZER U, DALAY N. Expression of the TRAIL receptors in blood mononuclear cells in leukemia. Pathol Oncol Res 2007; 13: 290-294. http://dx.doi.org/10.1007/BF02940307
40. VINDRIEUX D, REVEILLER M, CHANTEPIE J, YAKOUB S, DESCHILDRE C et al. Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAILinduced apoptosis. Cancer Cell Int 2011; 11: 42. http://dx.doi.org/10.1186/1475-2867-11-42
41. LALAOUI N, MORLE A, MERINO D, JACQUEMIN G, IESSI E et al. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One 2011; 6: e19679. http://dx.doi.org/10.1371/journal.pone.0019679
42. ZHU DM, SHI J, LIU S, LIU Y, ZHENG D. HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One 2011; 6: e18291. http://dx.doi.org/10.1371/journal.pone.0018291
43. MORIZOT A, MERINO D, LALAOUI N, JACQUEMIN G, GRANCI V et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2011; 18: 700-711. http://dx.doi.org/10.1038/cdd.2010.144
44. TOSCANO F, FAJOUI ZE, GAY F, LALAOUI N, PARMENTIER B et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene 2008; 27: 4161-4171. http://dx.doi.org/10.1038/onc.2008.52